Sort
85,873 grants matching “alzheimers”
Imaging Genomics of the Aging Brain
$813,065David C Glahn · Boston Children'S Hospital · R01 · FY2021 · AG
Targeting the miR-155 and APOE-TREM2 pathways to restore dysfunctional microglia in Alzheimerâs disease
$812,962Oleg Butovsky · Brigham And Women'S Hospital · R01 · FY2018 · AG
COBRE for Perinatal Biology
$812,903Sunil K Shaw · Women And Infants Hospital-Rhode Island · P30 · FY2017 · GM
Administrative Core
$812,777Oscar L. Lopez · University Of Pittsburgh At Pittsburgh · P30 · FY2023 · AG
Clinical Core
$812,764Christopher H Van Dyck · Yale University · P30 · FY2024 · AG
Cell-Type Specific Vulnerability to Tauopathy and Its Prevention in Multiple Models
$812,712Einar M Sigurdsson · New York University School Of Medicine · R01 · FY2025 · NS
Cell-Type Specific Vulnerability to Tauopathy and Its Prevention in Multiple Models
$812,712Einar M Sigurdsson · New York University School Of Medicine · R01 · FY2024 · NS
Building Community and Research Engagement among Sexual and Gender Minority Older Adults at Risk for Alzheimerâs Disease and Related Dementias
$812,655Whitney Lee Wharton · Emory University · R24 · FY2021 · AG
Molecular mechanism of bidirectional transport
$812,600William Olaf Hancock · Pennsylvania State University, The · R35 · FY2024 · GM
Regulation of tau expression in Alzheimer disease and aging
$812,585John Fonda Crary · Icahn School Of Medicine At Mount Sinai · R01 · FY2017 · AG
Traumatic Brain Injury Anti-Seizure Prophylaxis in the Medicare Program
$812,499Lidia Maria Veras Rocha De Moura · Massachusetts General Hospital · R01 · FY2025 · AG
Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.
$812,379Michael Mullan · Archer Pharmaceuticals, Inc. · R42 · FY2020 · AG
Neurotrophic Factors: Genetic Variation and Serum Levels in Brain Aging
$812,347Sudha Seshadri · Boston University Medical Campus · R01 · FY2009 · AG
digital InteGrated behavioral treatmeNt for comorbid obesITy and deprEssion among racial and ethnic adults age 50 and older (IGNITE)
$812,282Jun Ma · University Of Illinois At Chicago · R01 · FY2024 · AG
Delirium Dynamics: Understanding Causes and Effects
$812,175Eyal Yaacov Kimchi · Northwestern University At Chicago · R01 · FY2024 · AG
Novel imaging biomarkers of neuroinflammation in Alzheimer's disease
$812,030Mohammad Haris · University Of Pennsylvania · R01 · FY2025 · AG
Microglia contribution to disease pathogenesis in C9orf72 ALS/FTD
$811,977Rita Sattler · St. Joseph'S Hospital And Medical Center · R01 · FY2024 · NS
Elucidating changes in astrocyte subpopulations associated with resistance to Alzheimers Disease pathology in multi-ethnic cohorts
$811,964Vilas Menon · Columbia University Health Sciences · R01 · FY2020 · AG
Creating adaptive, wearable technologies to assess and intervene for individuals with ADRDs
$811,924Diane Joyce Cook · Washington State University · R35 · FY2025 · AG
Testing Olfaction in Primary care to detect Alzheimer's disease and other Dementias (TOPAD)
$811,920Jose A Luchsinger · Columbia University Health Sciences · R01 · FY2017 · AG
Natural History of Amyloid Deposition in Adults with Down Syndrome
$811,917Benjamin L Handen · University Of Pittsburgh At Pittsburgh · R01 · FY2009 · AG
Improving Focused Ultrasound Mediated Viral Gene Therapy Delivery
$811,897Bhavya Ramesh Shah · Ut Southwestern Medical Center · R01 · FY2025 · NS
Noninvasive Low-cost Biomarkers for Preclinical Diagnosis and Longitudinal Tracking of Alzheimer's Disease Using Sleep and Resting State EEG
$811,850Patrick L. Purdon · Massachusetts General Hospital · R01 · FY2021 · AG
Enhancing Sleep Quality for Nursing Home Residents with Dementia: Pragmatic Trial of an Evidence-Based Frontline Huddling Program
$811,849A Lynn Snow · University Of Alabama In Tuscaloosa · R61 · FY2019 · AG
Preclinical assessment of GCPII inhibitors for cognition and tau pathology
$811,824Amy F.t. Arnsten · Yale University · R01 · FY2020 · AG